Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Terence Flynn's rating is based on United Therapeutics' recent progress in the development of artificial organs, particularly with the UKidney, which has shown promising results in its first transplant. The UKidney, a xenotransplantation product, is derived from a pig with specific gene edits to enhance compatibility with humans, marking a significant advancement in their biotechnology initiatives.
Despite the potential upside these innovations could bring to United Therapeutics' estimates, the experimental nature of these developments and the pending regulatory approvals suggest a cautious approach. Flynn considers the ongoing preclinical studies and the anticipated human clinical trials starting in 2025 as factors that warrant a Hold rating, emphasizing the need for further validation and success in future trials.
Based on the recent corporate insider activity of 258 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.